EcoDrugPlus

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSPNAG00000028017
Gene Symbol: ATP4A
4 Cross references
183 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Beta

Ensembl ID : ENSPNAG00000001555
Gene Symbol: ATP4B
4 Cross references
184 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 1

Ensembl ID : ENSPNAG00000018818
Gene Symbol: ATP1A1
3 Cross references
150 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 1

Ensembl ID : ENSPNAG00000009768
Gene Symbol: ATP1A1
3 Cross references
201 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSPNAG00000027045
Gene Symbol: ATP1B1
3 Cross references
225 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2

Ensembl ID : ENSPNAG00000020664
Gene Symbol: ATP1B2
3 Cross references
236 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSPNAG00000020120
Gene Symbol: ATR
3 Cross references
206 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSPNAG00000000784
Gene Symbol: AXL
2 Cross references
187 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPNAG00000008630
Gene Symbol: BRAF
3 Cross references
220 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSPNAG00000016446
Gene Symbol: BCL2
4 Cross references
176 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSPNAG00000029279
Gene Symbol: BCL2
4 Cross references
168 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSPNAG00000013239
Gene Symbol: BCL2L1
3 Cross references
226 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).